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The aim of this study was to assess how an admission to an acute palliative-supportive care
unit (APSCU), may influence the therapeutic trajectory of advanced cancer patients.
Methods
A consecutive sample of advanced cancer patients admitted to APCU was assessed. The
following parameters were collected: patients demographics, including age, gender, pri-
mary diagnosis, marital status, and educational level, performance status and reasons for
and kind of admission, data about care-givers, recent anticancer treatments, being on/off
treatment or uncertain, the previous care setting, who proposed the admission to APSCU.
Physical and psychological symptoms were evaluated at admission and at time of dis-
charge. The use of opioids was also recorded. Hospital staying was also recorded. At time
of discharge the parameters were recorded and a follow-up was performed one month after
discharge.
Results
314 consecutive patients admitted to the APSCU were surveyed. Pain was the most fre-
quent reason for admission. Changes of ESAS were highly significant, as well as the use of
opioids and breakthrough pain medications (p <0.0005). A significant decrease of the num-
ber of “on therapy” patients was reported, and concomitantly a significant number of “off-
therapy” patients increased. At one month follow-up, 38.9% patients were at home, 19.7%
patients were receiving palliative home care, and 1.6% patients were in hospice. 68.5% of
patients were still living.
PLOS ONE | DOI:10.1371/journal.pone.0157300 June 22, 2016 1 / 10
a11111
OPEN ACCESS
Citation: Mercadante S, Adile C, Caruselli A, Ferrera
P, Costanzi A, Marchetti P, et al. (2016) The
Palliative-Supportive Care Unit in a Comprehensive
Cancer Center as Crossroad for Patients’ Oncological
Pathway. PLoS ONE 11(6): e0157300. doi:10.1371/
journal.pone.0157300
Editor: Daniele Santini, University Campus Bio-
Medico, ITALY
Received: April 6, 2016
Accepted: May 26, 2016
Published: June 22, 2016
Copyright: © 2016 Mercadante et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
Conclusion
Data of this study suggest that the APSCUmay have a relevant role for managing the thera-
peutic trajectory of advanced cancer patients, limiting the risk of futile and aggressive treat-
ment while providing an appropriate care setting.
Introduction
Cancer patients may develop relevant symptoms during the course of disease. They spend
more time in hospital wards for concurrent complications, uncontrolled symptoms, or to
receive aggressive therapies, even in last weeks of life [1]. Other than common symptoms due
to disease progression, anti-cancer toxicities represent a serious burden for cancer patients
often resulting in unplanned or planned hospital presentations. These aspects require expert
advice for facing complex clinical and psychological problems [2]
Palliative care is commonly provided at home, in hospice, or occasionally with mobile team
in hospitals, when available. Regrettably, in most countries specialized palliative care is pro-
vided only for 2–3 weeks before death [3]In a recent survey, in the last three months before
hospice admission, a large amount of patients were admitted to hospital for about five weeks,
and about half of patients had received chemotherapy. Most of these patients had a relevant
symptom burden and were undertreated. Almost all patients died in hospice within 2–3 weeks,
suggesting that hospice admission is only one way for end of life treatments [4]Similarly, it has
been reported that in the last months of life most patients spent about 1/3 of this period in hos-
pital, with half of them receiving chemotherapy in the last month of life [5]The mean survival
of cancer patients followed by a home palliative care team has been reported to be 6–7 weeks
[6]Indeed, many patients receive aggressive oncologic treatments even at the end of life and
futile treatments are often administered because the poor knowledge or experience of oncolo-
gists in palliative care [1,7–9]. In a prestigious institution in USA, the interval between pallia-
tive care referral and death was less than two months [10].This timing for palliative care is
inacceptable for patients who commonly present clinical problems early during the course of
disease.
Recent evidence strongly suggests to start palliative care in other settings, other than tradi-
tional home care and hospice, to intercept cancer patients early in the course of disease, rather
than limiting this intervention in the last weeks of life. An early referral to a palliative care team
should be optimal to provide immediate symptom relief, treatment of drug-induce toxicities,
education, and advice on the future therapeutic pathways [11–16]. In the last years, an
increased number of acute palliative-supportive care units (APSCU) in comprehensive cancer
centers has been developed. A specialistic team can meet the global needs of cancer patients at
any stage of disease to resolve the many physical and psychological problems occurring during
both the active treatment or the advanced stage of disease, including the delicate phase of end
of life [11–18].Several studies have reported the positive outcomes of APSCUs, that have been
shown to provide better outcomes and cost saving than palliative care consultation services
[13,19–25].However, the role of an APSCU admission in re-directing the oncologic pathway,
other than symptom control, has not well investigated. In other words, can an APSCU admis-
sion influence the therapeutic trajectory of advanced cancer patients? This outcome may have
a tremendous impact on patients’ care, avoiding further futile and expensive treatments while
providing a timely and appropriate intervention. The aim of this study was to assess how an
admission to an APSCU in a comprehensive cancer center can influence the therapeutic trajec-
tory of oncological patients and optimize consequently the resources.
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Material and Methods
The institutional review board at the University of Palermo approved the study and written
patients’ informed consent was obtained. The study was performed in an APSCU, devoted to
research and connected to the University of Palermo. This eight beds unit was established
about 15 years ago in a small comprehensive cancer center. The characteristics of this unit have
been described elsewhere [17].The goals of this unit are the control of pain and symptoms due
to disease, drug-related toxicities, providing advice to other units, and facilitate the transition
for care, when indicated.
A consecutive sample of advanced cancer patients who were admitted to an APSCU was
prospectively assessed for a period of 10 months. Advanced cancer was considered as locally
advanced, recurrent, or metastatic disease for solid cancers, and relapsed or refractory disease
for hematologic tumors. All patients underwent comprehensive and continuous symptom
assessment and management during their hospital stay at APSCU [17]. At discharge, patients’
situation was reviewed and eventually an oncologic consultation was asked to decide the next
therapeutic steps.
Data Collection
Patients demographics, including age, gender, primary diagnosis, marital status, and educa-
tional level were collected. Performance status and reasons for admission were recorded,
including pain or opioid-related problems, toxicity from chemotherapy, symptom control, re-
evaluation, or end-of-life issues. The kind of admission was also characterized as unplanned or
planned admission. Eventual re-admissions and their principal indications, and time from the
previous admission, were recorded. Data regarding people living with the patients were gath-
ered. A care giver was considered as a person who spent at least 4 hours/day with the patient.
Patients’ and caregivers’ awareness of prognosis was assessed by semi-structured interviews
(complete, partial, absent). The following data were also recorded: chemotherapy in the last 30
days, or other anticancer treatments (radiotherapy, surgery, target therapy, hormonal therapy,
and so on), on/off treatment or uncertain, that is when the need of oncologic treatment
remained to be established and physicians delay taking a decision. It was also recorded the pre-
vious care setting, including home, hospital unit, day-hospital, or other hospitals, and who
referred the patient to the unit, including home palliative care physicians, oncologists, other
units, other hospitals, or general practitioner (GP).
Physical and psychological symptoms were evaluated by Edmonton Symptom Assess-
ment Scale (ESAS) at admission and at time of discharge (or the day before death). ESAS is a
self-reported tool assessing the intensity of most common psychological and physical symp-
toms on a 0 to 10 numerical scale, rated on the average score in the previous 24-hour period.
ESAS is a valid and reliable tool for assessing the overall symptom burden, sensible to
changes produced by a treatment [26,27].A screening test for history of alcohol dependence
(CAGE: cut down, annoy, guilt, eye-opener) was also administered [28].The Memorial delir-
ium Assessment Scale (MDAS) was used to assess the cognitive status of patients. MDAS is
a validated tool to quantify the intensity of delirium [29].Analgesic drugs and their doses at
admission and discharge were recorded. Hospital staying was also recorded. At time of dis-
charge the outcome and subsequent referral to other care settings (death, home, home care,
hospice, oncology), and the pathway of oncologic treatment were re-considered (on/off,
uncertain). One month after discharge, patients or their relatives were contacted by phone
to gather information on the care setting, if the patients were continuing anticancer thera-
pies, or died.
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Statistical Analysis
Statistical analysis of quantitative and qualitative data, including descriptive statistics, was per-
formed for all items. Continuous data were expressed as mean ± standard deviation (SD),
unless otherwise specified. Frequency analysis was performed using the Pearson’s chi-square
test and Fisher exact test, as needed. The univariate analysis of variance was used for paramet-
ric analysis; the paired samples Student's t-test was used to compare symptom intensity and
opioid dosage, respectively, at the different intervals. Data were analyzed by IBM SPSS Software
22 version (IBM Corp., Armonk, NY, USA). All p-values were two-sided and p<0.05 was con-
sidered statistically significant.
Results
314 consecutive cancer patients admitted to the APSCU were surveyed. For the different
parameters taken into consideration, data were missed for less than 10% of patients (range
0–20 patients). The characteristics of patients, stage of disease, kind of admission (urgent, read-
mission etc), information regarding relatives and the caregiver, educational level, indications
for admission, active treatments in the last two weeks, and patients’ and caregivers’ awareness
of disease are presented in Table 1.
Most admissions were planned, but a consistent number of patients admitted on emergency
(generally from the oncological day-hospital) or transferred from other hospital units. The
mean hospital stay was 6.9 days (SD 6.3). Twelve patients (3.8%) died in the unit. A significant
number of patients were assigned to home palliative care or hospice admission at time of
discharge.
Table 1. Characteristics of patients.
Patients 314
Age (yrs, mean SD) 65.7 (12)
Gender 132 F /182 M













Locally advanced 49 (15.6%)
Metastatic 238 (75.8%)
No evidence of disease 27 (8.6%)
People living with the patients
Alone 27 (8.6%)
Partner 123 (39.2%)
Partener and/or sons/daughters 287 (91.4%)
Nursing home 4 (1.3%)
(Continued)
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Data regarding on how the patient was considered for treatment purposes (on/off, or uncer-
tain), the setting where patients were previously cared, who referred the patient for admission,
and clinical pathways suggested at discharge from the unit, are presented in Table 2.
At discharge a significant decrease of the number of “on therapy” patients was reported,
and concomitantly the number of “off-therapy” patients increased. Regarding the possible rela-
tionships with the parameters considered, both epidemiological and sociocultural, younger
patients, females, and diagnosis of breast cancer were more likely to be “on therapy” (p = 0.029,
p = 0.0005, and p = 0.010, respectively). Younger patients and patients who had a high Kar-
nofsky status were more likely to be discharged home (p = 0.021, and p =<0.0005, respec-
tively). No other significant relationships with clinical and sociocultural variables were found.
Changes in ESAS and Analgesic Drugs
ESAS at time of admission and at discharge (one day before death in patients who died) are
presented in Table 3. The difference was highly significant for all the items. At admission 197
Table 1. (Continued)
Presence of care-giver 265 (84.4%)
Education
No school 12 (3.8%)
Primary 103 (32.8%)
Secondary school 98 (31.2%)
High level 61 (19.4%)
Degree 40 (12.8%)
Disease awareness Patient Care-giver
Complete 165 (52.5%) 269 (85.7%)
Partial 120 (38.2%) 36 (11.5%)
Absent 29 (9.2%) 9 (2.8%)
Admission
Planned admission 246 (78.3%)
Unplanned admission 55 (17.5%)
Transfer from other units 13 (4.2%)
Indications for admission
(multiple choice)
Uncontrolled pain 231 (73.6%)
Opiod-related toxicity 61 (19.4%)
Anticancer toxicity 58 (18.5%)
Other symptoms 182 (58%)
End of life care 25 (8%)
Treatments in the previous 30
days
Chemotherapy 97 (30.9%)
Chemotherapy + target therapy 8 (2.5%)
Chemotherapy + radiotherapy 3 (1%)
Target therapy 17 (5.4%)
Radiotherapy 6 (1.9%)
Hormonal therapy 12 (3.8%)
Hormonal + target therapy 2 (0.6%)
Surgery 29 (9.2%)
doi:10.1371/journal.pone.0157300.t001
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patients were receiving opioids (in a rank order: n.38 oxycodone/naloxone, n.23 transdermal
fentanyl, n.17 codeine, n.15 morphine, n.14 hydromorphone, n.12 methadone, n.12 tapentadol,
and others). At discharge 236 patients were prescribed opioids (in a rank order: n.44 hydro-
morphone, n.30 transdermal fentanyl, n.28 methadone, n.22 morphine, n.20 oxycodone/nalox-
one, n.13 transdermal buprenorphine, and others). The difference was significant (p = 0.001).
Oral morphine equivalents at admission and at discharge were 190 mg (SD 162), and 215 mg
(SD 121), respectively.
Table 2. Data regarding the previous disease-oriented treatment, the setting where patients were previously cared and who referred the patient at











at admission proposed at discharge P
Home 256 (81.5%) 203 (64.6%) <0.0005
Home palliative care 28 (8.9%) 92 (29.3%) <0.0005
Hospice 0 12 (3.8%) <0.0005
Oncology 4 (1.3%)
Other units 14 (4.5%)
Emergency 4 (1.3%)
Other hospitals 8 (2.5%) 7 (2.3%) 1.0
Disease-oriented treatment
at admission proposed at discharge P
On 150 (47.8%) 105 (33.4%) <0.0005
Off 73 (23.2%) 103 (32.8%) 0.0043
Uncertain 65 (20.7%) 74 (23.6%) 0.441
None 14 (4.5%) 18 (5.7%) 0.586
Follow-up 12 (3.8%) 14 (4.5%) 0.842
doi:10.1371/journal.pone.0157300.t002
Table 3. ESAS items at admission and at discharge in patients with complete data.
N at admission at discharge P
Pain 263 5.26 (2.83) 2.59 (1.98) 0.001
Weakness 263 5.64 (2.82) 3.27 (2.67) 0.001
Nausea 259 1.96 (2.77) 0.90 (1.89) 0.001
Depression 261 3.15 (2.03) 1.69 (2.21) 0.001
Anxiety 260 2.94 (3.06) 1.68 (2.31) 0.001
Drowsiness 260 4.18 (2.70) 2.86 (2.60) 0.001
Dyspnea 261 2.34 (3.14) 1.34 (2.26) 0.001
Insomnia 262 4.44 (3.25) 2.64 (2.82) 0.001
Appetite 260 5.88 (2.31) 2.92 (2.72) 0.001
Well being 253 38.79 (18.34) 3.60 (2.21) 0.001
Total 263 38.79 (18.34) 20.01 (15.7) 0.001
doi:10.1371/journal.pone.0157300.t003
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At admission, 197 patients were receiving a breakthrough pain medication (in a rank order:
n. 56 non-opioid analgesics, n.51 transmucosal fentanyl products, n.30 oral morphine, and oth-
ers). At discharge, 247 patients were receiving a breakthrough pain medication, principally rep-
resented by opioids (in a rank order: n.83 oral morphine, n.76 transmucosal fentanyl products,
and others). The difference was significant (p<0.0005).
Re-Admissions
Seventy-five patients (23.9%) were readmitted, being 42 (13.4%), 15 (4.8%), and 9 (2.9%)
patients previously admitted once, twice, and three times, respectively. Some patients had been
admitted several times before (5–20 admissions) in a range of 4–24 months. The reasons for
readmission were pain (72 patients) or/and opioid-related effects (11 patients), chemotherapy-
related toxicity (11 patients), symptom control (34 patients), end of life care (2 patients). The
mean number of days from the last admission was 71 days (SD 171).
Follow-Up at One Month after Discharge
14 patients (4.5%) were lost at follow up (after 3 phone attempts). One patient or the relative
(0.3%) refused the interview. Information regarding the oncologic treatment was available for
215 (68.5%) patients. 94 (29.9%) patients were continuing anticancer treatments, 83 (26.4%)
were off-therapy, while in 38 (13.2%) patients the decision was uncertain.
Information regarding the setting of care was unavailable for 100 (31.8%) patients. 122
(38.9%) patients were at home, 62 (19.7%) patients were receiving palliative home care, 5
(1.6%) patients were in hospice. For 25 (8%) patients information was imprecise.
215 patients (68.5%) were still living, 59 patients (18.8%) died at home, two patients died in
hospice (0.6%), two patients died in another hospital (0.6%), two patients (0.6%) died in an
intensive care unit.
Discussion
The admission to a specialized APSCU resulted in a decrease in the number of patients con-
tinuing an anticancer treatment. This corresponds to a clear change in direction of the clinical
trajectory. Moreover, the number of patients who were deemed to continue palliative care at
home or in hospice increased, allowing them to be cared in a more appropriate setting. Of
interest, hospital stay and mortality rate was extremely low, confirming the specificity of the
APSCU. Finally, a dramatic improvement in symptom intensity as well toxicity from oncologic
treatments was achieved in a short period of time. Taken together these data suggest the an
APSCU admission is not only useful for symptom control or toxicities in complex clinical con-
ditions, but also to allow an appropriate patients’ assessment according to more strict palliative
care criteria and a multidisciplinary evaluation of the therapeutic options for individuals.
Moreover, some patients may be more appropriately referred to territory resources including
home palliative care or hospice. In other words, an APSCU may be a cross-road for advanced
cancer patients, switching the lights for the right moment to turn their way.
Many studies have reported the advantages of early palliative care when integrating onco-
logic treatment, advocating a better quality of life and a longer survival [29–31].However, in
these clinical trials, both best supportive care arm and control-arm were poorly defined. As a
consequence the risk of over-estimating the effect is high. Moreover, none of these studies doc-
umented evidence-based symptom management or modalities of access to palliative care ser-
vices [32].Regardless of the difficulties in finding an evidence of such a complex issue,
oncological departments are the ideal setting to provide multidisciplinary and simultaneous
care during all the phases of disease. It is of paramount importance that palliative care starts
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where the patients are, rather than in other settings where only end-of-life care can be offered
for just a few weeks. Some aspects of oncology services deserve particular attention. For exam-
ple, an outpatient clinic for managing unplanned presentations of cancer patients with drug-
induced toxicity and cancer symptoms, provided an improvement of quality of oncology ser-
vices, avoiding inappropriate admissions and interferences with the ordinary work-plan [2].
Relevant issues relative to the impact of a APSCU in an oncologic department have been
recently raised [11–13,15]. It has been described as hospital palliative care may increase the use
of palliative care services and the likelihood of dying at home, rather than in hospital [33].Our
findings also suggest both a cost and quality incentive for oncological departments to develop
APSCU [14,22]. A specialized integrated supportive care team working within the oncology
unit may contribute to inpatient costs reduction [34].
At present, APSCUs are available only in a some medical centres in USA [11,15,20]. but not
in Europe, where the traditional hospice based approach, inherited from UK tradition, prevails.
Even in these centres, the intervals between advanced disease and death, advanced disease and
palliative care referral, and palliative care referral and death, were on average 9.4, 5.6, and 1.9
months, respectively [10]More recently, in a multinational European study it has been reported
that transitions of care occur late, with 17–27% patients starting palliative care in the last week
of life. The majority of patients had severe symptom distress in the last week of life and 33% of
patients died in hospital. This finding indicates that further integration of palliative care into
oncology care is required in most countries [35].Numerous studies suggest that inpatient units
improve symptoms, reduce hospital costs, coordinates care, and reduces inappropriate hospital
admissions [36].
There are some limitations regarding the interpretation of data of the present study. This
was a single-centre experience and could not reproduced extensively. However, this model,
together with those of other North American institutions which have largely provided their
data [12]. could be useful for a possible propagation in oncological departments. There is an
increasing number of centers of integrated oncology and palliative care, which could poten-
tially provide comprehensive services in supportive and palliative care as part of their routine
care. Another limitation is represented by the lack of a control arm. As reported in a recent
review, it is quite difficult to select a controlled arm in this population, also from an ethical
point of view.
In conclusion, data of this study suggests that the presence of APSCU in a comprehensive
cancer center may have a relevant role for managing the therapeutic trajectory of advanced
cancer patients, limiting the risk of futile and aggressive treatment while providing an appro-
priate care setting. Moreover, a broad and comprehensive intervention including the manage-
ment of cancer–related complex symptoms and toxicities due to oncologic treatments, as well
end of life care issues, may improve patients’ care with a short hospital stay and consequently
reduced costs. The American Society of Clinical Oncology has progressively increased the visi-
bility of palliative care and has developed education tools to improve oncologist skills in pallia-
tive care to facilitate the integration of both processes simultaneously, rather than in a
sequential way, just confining palliative care at the end of life. These attitudes may also reduce
aggressiveness of cancer care near the end of life [1].The approach presented in this study sug-
gests that the most effective way to improve the care of cancer patients would be to develop for-
mal structures within each oncological department to provide a standardized and integrated
approach. The knowledge of these findings would be useful to national policy makers to modify
former and old-fashioned policies, to optimize the economic resources, and to improve
patients’ care.
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